Anna Sureda (@annasureda5) 's Twitter Profile
Anna Sureda

@annasureda5

Haematologist interested in lymphomas, stem cell transplantation and CART cells. #CART #BMT #lymphomas #immunotherapy #WomenInMedicine. President of EBMT

ID: 1330231762543370241

calendar_today21-11-2020 19:29:09

9,9K Tweet

4,4K Followers

2,2K Following

Chimeric Antigen Receptor T-Cell (CAR-T) & Gene Rx (@carttherapy) 's Twitter Profile Photo

Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial - The Lancet Oncology thelancet.com/journals/lanonโ€ฆ

The EBMT Trainee Committee (@theebmt_trainee) 's Twitter Profile Photo

8โƒฃImmersive, Interactive Learning with Global Experts Go beyond lectures โ€” #ITCTC25 features case-based discussions, expert Q&As, and audience interaction, ensuring a dynamic and memorable learning experience. ebmt.org/events/10th-inโ€ฆ

Claire Roddie (@drclaireroddie) 's Twitter Profile Photo

Check out how CD19CAR-T for Richters Transformation stacks up in this UK analysis. Broadly safe and effective, ORR 70%, 2y PFS 46%. Risks for poor response- high LDH, non-response bridging, more prior lines. โฆUCL Cancer Instituteโฉโฉ โฆSatyen Gohilโฉ โฆ onlinelibrary.wiley.com/doi/10.1111/bjโ€ฆ

Sabrina Ranero Ferrari (@sabrinaranero) 's Twitter Profile Photo

๐Ÿ”ฌ Curious about the role of the microbiome in lymphomas? Join WiLing Wednesdays โ€” July 16, 3pm EST! Dr. Diefenbach & Dr. Paola Ghione MD, MSEpi will dive into it all. ๐Ÿงฌ Free & open to all! ๐Ÿ”— Register now: us06web.zoom.us/webinar/registโ€ฆ #WomenInLymphoma #Lymphoma #Microbiome

The EBMT Trainee Committee (@theebmt_trainee) 's Twitter Profile Photo

9โƒฃReady to shape the future?๐Ÿš€ Join us at #ITCTC25 โ€” where leaders grow๐Ÿ”ฅ ๐Ÿ“ธPast committee, forever proud. ๐Ÿ’ฌBe heard. Be bold. ebmt.org/events/10th-inโ€ฆ

9โƒฃReady to shape the future?๐Ÿš€
Join us at #ITCTC25 โ€” where leaders grow๐Ÿ”ฅ
๐Ÿ“ธPast committee, forever proud.
๐Ÿ’ฌBe heard. Be bold.

ebmt.org/events/10th-inโ€ฆ
Women in Lymphoma - wil@lymphoma.org.au (@womeninlymphoma) 's Twitter Profile Photo

Do infectious agents drive lymphoma initiation? Find out next week during the 3rd webinar of the Pathogens and Lymphoma Series with Catharine Thieblemont, Ayako Arai, Amira Marouf, Florence Broussais-Guillaumot and Soni Smith MD Register โžก๏ธ us06web.zoom.us/webinar/registโ€ฆ

Do infectious agents drive lymphoma initiation? 
Find out next week during the 3rd webinar of the Pathogens and Lymphoma Series with Catharine Thieblemont, Ayako Arai, Amira Marouf, Florence Broussais-Guillaumot and <a href="/SoniSmithMD/">Soni Smith MD</a> 
Register โžก๏ธ us06web.zoom.us/webinar/registโ€ฆ
Juan P. Alderuccio (@juanalderuccio) 's Twitter Profile Photo

Our group's latest publication demonstrates the correlation between PET/CT-derived body composition and outcome in DLBCL. #DeepLearning #lymsm #lymphoma Sylvester Comprehensive Cancer Center CRANE Lab Craig Moskowitz, MD UMiami Health System ascopubs.org/doi/10.1200/CCโ€ฆ

@sehh_es (@sehh_es) 's Twitter Profile Photo

#destacadoSEHH | El curso de terapias avanzadas de la UMU refuerza el papel clรญnico de la investigaciรณn acadรฉmica immedicohospitalario.es/noticia/52199/โ€ฆ a travรฉs de IM Mรฉdico

Alexandra Pedraza, MD, PhD (@drapedraza) 's Twitter Profile Photo

Muy orgullosas de nuestras residentes, ahora adjuntas!!! ๐Ÿ‘ฉ๐Ÿปโ€๐ŸŽ“ Ares Guardia te deseamos lo mejor en esta nueva etapa!!๐Ÿ‘๐Ÿผ๐ŸŽ‰๐ŸŽ‰ Caminar

Muy orgullosas de nuestras residentes, ahora adjuntas!!! ๐Ÿ‘ฉ๐Ÿปโ€๐ŸŽ“ <a href="/GuardiaAres/">Ares Guardia</a> te deseamos lo mejor en esta nueva etapa!!๐Ÿ‘๐Ÿผ๐ŸŽ‰๐ŸŽ‰ <a href="/Caminar59675080/">Caminar</a>
Josep Domingo-Domenech (@domingodomenech) 's Twitter Profile Photo

Interesting interview to Eva Domingo-Domenech Institut Catalร  d'Oncologia and othersโ€ฆ in Spanish media, highlighting new developments in precision oncology and clinical trials impacting on hematological cancer patients care ๐Ÿ‘ ๐Ÿ‘ ๐Ÿ‘!

Interesting interview to <a href="/Evadodo23/">Eva Domingo-Domenech</a> <a href="/ICO_oncologia/">Institut Catalร  d'Oncologia</a> and othersโ€ฆ in Spanish media, highlighting new developments in precision oncology and clinical trials impacting on hematological cancer patients care ๐Ÿ‘ ๐Ÿ‘ ๐Ÿ‘!
Irene Garcรญa-Cadenas (@irenedenuevo) 's Twitter Profile Photo

Nuevo estudio del grupo de complicaciones infecciosas del GETH. Papel del tiempo de duplicaciรณn en la era Letermovir. onlinelibrary.wiley.com/doi/10.1111/tiโ€ฆ

Felipe Peรฑa Muรฑoz (@hematorules) 's Twitter Profile Photo

#MIR21 Felicidades a todos los #HematoRulers que terminan hoy su residencia! Muy merecido! A disfrutar esta nueva etapa del camino, seguiremos just creciendo y aprendiendo! #HematoMola!

Sabrina Ranero Ferrari (@sabrinaranero) 's Twitter Profile Photo

Do infectious agents drive lymphoma initiation? ๐Ÿฆ  Join us ! 3rd webinar in Pathogens & Lymphoma series with global experts: ๐Ÿ”น Catherine Thieblemont - Ayako Arai ๐Ÿ”น Florence Broussais, Amira Marouf, Somali Smith ๐Ÿ—“ July 23, 2025 โ€“ 4PM EST Register now:lnkd.in/gVEZGcRB

Sara Redondo Velao (@sarared69478633) 's Twitter Profile Photo

๐Ÿ“ฃ Finally out!! Reduced doses of PTCy (60mg/kg total dose) combined with tacrolimus preserves key clinical outcomes while potentially reducing acute hematological and infectious toxicity. doi.org/10.1111/ejh.70โ€ฆ

Lymphoma Hub (@lymphomahub) 's Twitter Profile Photo

๐Ÿ“โ€ฏA presentation by Julie Vose during the Lymphoma Hub symposium at #18ICML highlighted the current unmet needs for the treatment of patients with MCL. Learn more: loom.ly/zhVtS3s #Lymphoma #lymsm #MedEd

๐Ÿ“โ€ฏA presentation by <a href="/DrJulieVose/">Julie Vose</a> during the Lymphoma Hub symposium at #18ICML highlighted the current unmet needs for the treatment of patients with MCL.

Learn more: loom.ly/zhVtS3s

#Lymphoma #lymsm #MedEd
IACH (@theiach) 's Twitter Profile Photo

๐ŸŽ‰๐—–๐—ผ๐—ป๐—ด๐—ฟ๐—ฎ๐˜๐˜‚๐—น๐—ฎ๐˜๐—ถ๐—ผ๐—ป๐˜€ ๐˜๐—ผ ๐—ฃ๐—ฟ๐—ผ๐—ณ. ๐— ๐—ฎ๐—ฟ๐—ถฬ๐—ฎ-๐—ฉ๐—ถ๐—ฐ๐˜๐—ผ๐—ฟ๐—ถ๐—ฎ ๐— ๐—ฎ๐˜๐—ฒ๐—ผ๐˜€ ๐˜š๐˜ฉ๐˜ฆ ๐˜ฉ๐˜ข๐˜ด ๐˜ฃ๐˜ฆ๐˜ฆ๐˜ฏ ๐˜ข๐˜ธ๐˜ข๐˜ณ๐˜ฅ๐˜ฆ๐˜ฅ ๐˜ต๐˜ฉ๐˜ฆ ๐—ช๐—ฎ๐—น๐—ฑ๐—ฒ๐—ป๐˜€๐˜๐—ฟ๐—ผฬˆ๐—บ ๐—Ÿ๐—ถ๐—ณ๐—ฒ๐˜๐—ถ๐—บ๐—ฒ ๐—”๐—ฐ๐—ต๐—ถ๐—ฒ๐˜ƒ๐—ฒ๐—บ๐—ฒ๐—ป๐˜ ๐—”๐˜„๐—ฎ๐—ฟ๐—ฑ ๐˜›๐˜ฉ๐˜ช๐˜ด ๐˜ข๐˜ธ๐˜ข๐˜ณ๐˜ฅ ๐˜ช๐˜ด ๐˜จ๐˜ช๐˜ท๐˜ฆ๐˜ฏ ๐˜ต๐˜ฐ ๐˜ข ๐˜ณ๐˜ฆ๐˜ด๐˜ฆ๐˜ข๐˜ณ๐˜ค๐˜ฉ๐˜ฆ๐˜ณ

๐ŸŽ‰๐—–๐—ผ๐—ป๐—ด๐—ฟ๐—ฎ๐˜๐˜‚๐—น๐—ฎ๐˜๐—ถ๐—ผ๐—ป๐˜€ ๐˜๐—ผ ๐—ฃ๐—ฟ๐—ผ๐—ณ. ๐— ๐—ฎ๐—ฟ๐—ถฬ๐—ฎ-๐—ฉ๐—ถ๐—ฐ๐˜๐—ผ๐—ฟ๐—ถ๐—ฎ ๐— ๐—ฎ๐˜๐—ฒ๐—ผ๐˜€

๐˜š๐˜ฉ๐˜ฆ ๐˜ฉ๐˜ข๐˜ด ๐˜ฃ๐˜ฆ๐˜ฆ๐˜ฏ ๐˜ข๐˜ธ๐˜ข๐˜ณ๐˜ฅ๐˜ฆ๐˜ฅ ๐˜ต๐˜ฉ๐˜ฆ
๐—ช๐—ฎ๐—น๐—ฑ๐—ฒ๐—ป๐˜€๐˜๐—ฟ๐—ผฬˆ๐—บ ๐—Ÿ๐—ถ๐—ณ๐—ฒ๐˜๐—ถ๐—บ๐—ฒ ๐—”๐—ฐ๐—ต๐—ถ๐—ฒ๐˜ƒ๐—ฒ๐—บ๐—ฒ๐—ป๐˜ ๐—”๐˜„๐—ฎ๐—ฟ๐—ฑ

๐˜›๐˜ฉ๐˜ช๐˜ด ๐˜ข๐˜ธ๐˜ข๐˜ณ๐˜ฅ ๐˜ช๐˜ด ๐˜จ๐˜ช๐˜ท๐˜ฆ๐˜ฏ ๐˜ต๐˜ฐ ๐˜ข ๐˜ณ๐˜ฆ๐˜ด๐˜ฆ๐˜ข๐˜ณ๐˜ค๐˜ฉ๐˜ฆ๐˜ณ
Mehdi Hamadani, MD (@medihumdani) 's Twitter Profile Photo

HGBCL-NOS: We identify another histology with relatively CAR resistant relapse. N=111, most axi-cel, 2 year OS and PFS 42% and 29%. NRM 3%. #lymsm #cibmtr BJH | Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/bjโ€ฆ